Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in AVO?
Advanced Oncotherapy: THE INVESTMENT CASE

Advanced Oncotherapy secures £37.4mln of new financing

The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
Harley Street sign
INVESTMENT OVERVIEW: AVO The Big Picture
The proton therapy system is being installed at a facility in Harley Street, London

Shares of Advanced Oncotherapy PLC (LON:AVO), the developer of next-generation proton therapy systems for cancer treatment, shot up 30% after it secured £37.4mln of fresh funding, with £30mln of this coming from a new Chinese investor.

The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre.

READ: Advanced Oncotherapy making significant progress; in stronger position to assess funding options

The cash will come in three distinct tranches. Yantai CIPU Medical Technology, a medical devices firm based in the People’s Republic, is directly investing in Advanced Oncotherapy. It is acquiring £13.5mln in shares at 30p each, giving it a 29.9% stake in the business.

It is also paying £16.5mln for the rights to sell the LIGHT system China, Macau, Taiwan, Hong-Kong and South Korea.

Funding from investors

A further £7.4mln will come from other equity investors who are also buying stock at 30p each, which represents a 10% discount to last night’s closing price.

Chief executive Nicolas Serandour said he was delighted to have concluded a deal that brought in longer-term financing as well as a new, experienced strategic partner.

READ: Advanced Oncotherapy on track with development of first LIGHT system as it checks off another key milestone

"This deal is consistent with our strategy to focus our resources on the technological development of the first LIGHT system and to establish partnerships with those businesses that have a strong track record of market access and a unique expertise in their own geographies,” he added.

“With our long-term financing arrangements now well engaged we can continue to focus on making our unique proton therapy technology available to patients around the world."

The company in its update said work with Metric Capital Partners to conclude a £24mln loan facility continues.

“Terms and conditions are being updated to reflect the developments since the initial announcement of the agreement with Metric in May 2016,” it added.

Shares motor

The shares, up 132% in the last week, advanced 13p to 46p in morning trade. That's an immediate 10p a share profit for investors who backed the latest fundraiser.

LIGHT stands for Linac Image Guided Hadron Technology. The kit is cheaper and smaller than the current units, which are almost prohibitively expensive.

It has the ability to propel protons at the speeds generated by much larger machines.

The proton accelerator used by Advanced Oncotherapy was licensed from CERN, the European Organisation for Nuclear Research, which is currently hunting the ‘God particle’.

Increasing demand for proton therapy

“There is an increasing demand for proton therapy globally, with millions of patients who could potentially benefit from this technology,” said chairman, Dr Michael Sinclair recently.

“While the access to this technology remains scarce, there is a significant unmet medical need the LIGHT system is uniquely suited to provide.

“We are in a prime position to provide a novel and disruptive technology that advances current methods of cancer treatment in the UK and worldwide.

“There is mounting evidence for the clinical superiority of proton therapy over traditional X-ray radiotherapy.

“This evidence will only increase as more proton beam centres are built and more patients are treated. LIGHT's modularity and linear design allow for mass production, shorter manufacturing lead times, easier installation/commissioning and offer both cost and clinical advantages.”

View full AVO profile View Profile

Advanced Oncotherapy Timeline

Related Articles

1511808112_surgeon.jpg
January 09 2018
The device can now be sold to aid in heart treatment throughout the European Union
1511901712_biotech_517925923.jpg
November 29 2017
The company has developed a "unique and superior pressure" cycling technology (PCT), says Zacks.
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use